Loading
The point at which a cancer is judged to be growing again despite treatment, usually a 20% increase on scans or a new lesion (RECIST). It ends progression-free survival, usually triggers a change of treatment, and defines 'lines' of therapy.
Progression is assessed on scheduled scans (every 6-12 weeks in trials), so recorded progression dates depend on imaging frequency; blinded central review reduces investigator bias. Immunotherapy introduced pseudoprogression (apparent growth from immune infiltration before shrinkage), handled by iRECIST's 'unconfirmed progression' category, and hyperprogression (rapid acceleration in a minority). Molecular progression (rising ctDNA or PSA) precedes radiographic progression by months and is now used to trigger treatment switches in trials (SERENA-6). Oligoprogression, growth at one or a few sites while the rest is controlled, is treated with local therapy while continuing the systemic drug.
Shares Complete response (CR) and partial response (PR), RECIST, Progression-free survival (PFS).
Shares RECIST, Progression-free survival (PFS), Circulating tumour DNA (ctDNA).
Shares RECIST, Oligometastatic disease.
Shares Therasse 2000: RECIST, the standard rules for measuring whether a tumour responds, RECIST.
Shares RECIST, Oligometastatic disease.
Shares RECIST, Progression-free survival (PFS).
Shares RECIST, Progression-free survival (PFS), Circulating tumour DNA (ctDNA).
Shares RECIST, Progression-free survival (PFS).